Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.
2.

New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.

English C, Aloi JJ.

Clin Ther. 2015 Apr 1;37(4):691-715. doi: 10.1016/j.clinthera.2015.03.001. Epub 2015 Apr 4. Review.

PMID:
25846320
3.

Teriflunomide for multiple sclerosis.

He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.

Cochrane Database Syst Rev. 2016 Mar 22;3:CD009882. doi: 10.1002/14651858.CD009882.pub3. Review.

PMID:
27003123
4.

Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.

Tramacere I, Del Giovane C, Salanti G, D'Amico R, Filippini G.

Cochrane Database Syst Rev. 2015 Sep 18;(9):CD011381. doi: 10.1002/14651858.CD011381.pub2. Review.

PMID:
26384035
5.

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM.

J Manag Care Pharm. 2009 Sep;15(7):543-55.

6.

Rituximab for relapsing-remitting multiple sclerosis.

He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H.

Cochrane Database Syst Rev. 2013 Dec 6;(12):CD009130. doi: 10.1002/14651858.CD009130.pub3. Review.

PMID:
24310855
7.

Dimethyl fumarate for multiple sclerosis.

Xu Z, Zhang F, Sun F, Gu K, Dong S, He D.

Cochrane Database Syst Rev. 2015 Apr 22;(4):CD011076. doi: 10.1002/14651858.CD011076.pub2. Review.

PMID:
25900414
8.

Teriflunomide for multiple sclerosis.

He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;3:CD009882.

PMID:
23235682
9.

Established and novel disease-modifying treatments in multiple sclerosis.

Cross AH, Naismith RT.

J Intern Med. 2014 Apr;275(4):350-63. doi: 10.1111/joim.12203. Epub 2014 Mar 11. Review.

10.

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

Wingerchuk DM, Carter JL.

Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002. Review.

PMID:
24485135
11.

Laquinimod for multiple sclerosis.

He D, Han K, Gao X, Dong S, Chu L, Feng Z, Wu S.

Cochrane Database Syst Rev. 2013 Aug 6;(8):CD010475. doi: 10.1002/14651858.CD010475.pub2. Review.

PMID:
23922214
12.

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.

Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M.

Mult Scler Relat Disord. 2016 Sep;9:23-30. doi: 10.1016/j.msard.2016.06.001. Epub 2016 Jun 8. Review.

PMID:
27645339
13.

An update on new and emerging therapies for relapsing-remitting multiple sclerosis.

Weinstock-Guttman B.

Am J Manag Care. 2013 Nov;19(17 Suppl):s343-54. Review.

14.

Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.

Thomas RH, Wakefield RA.

Am J Health Syst Pharm. 2015 Jan 1;72(1):25-38. doi: 10.2146/ajhp140023. Review.

PMID:
25511835
15.

Update on disease-modifying therapies for multiple sclerosis.

Vargas DL, Tyor WR.

J Investig Med. 2017 Jun;65(5):883-891. doi: 10.1136/jim-2016-000339. Epub 2017 Jan 27.

PMID:
28130412
17.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
18.

Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.

Dashputre AA, Kamal KM, Pawar G.

J Manag Care Spec Pharm. 2017 Jun;23(6):666-676. doi: 10.18553/jmcp.2017.23.6.666.

19.

The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.

Dorman E, Kansal AR, Sarda S.

J Med Econ. 2015;18(12):1085-91. doi: 10.3111/13696998.2015.1076826. Epub 2015 Sep 21.

PMID:
26390149
20.

First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Johnston J, So TY.

Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000. Review.

PMID:
22642799

Supplemental Content

Support Center